Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CYCN | US
0.41
16.40%
Healthcare
Biotechnology
30/06/2024
21/10/2024
2.91
2.35
2.91
2.35
Cyclerion Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovering development and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463) a CNS-penetrant soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat an orally administered systemic sGC stimulator which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics Inc. for the development manufacture medical affairs and commercialization of pharmaceutical products including pharmaceutical compound and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge Massachusetts.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
97.0%1 month
82.6%3 months
107.9%6 months
150.2%-
-
0.69
-
-
0.56
0.52
-
-9.58M
7.32M
7.32M
-
-
-
14.10
-150.25
2.56
0.65
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.64
Range1M
0.65
Range3M
1.58
Rel. volume
2.37
Price X volume
70.54K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
TFFP | TFFP | Biotechnology | 2.3 | 7.97M | 11.11% | n/a | 1.26% |
Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 1.73 | 7.74M | 3.28% | n/a | 0.00% |
Moleculin Biotech Inc | MBRX | Biotechnology | 2.67 | 7.59M | 3.29% | n/a | 3.00% |
Pulmatrix Inc | PULM | Biotechnology | 2.04 | 7.45M | 0.97% | n/a | 0.18% |
Orgenesis Inc | ORGS | Biotechnology | 1.53 | 7.30M | -27.49% | n/a | -84.02% |
Virax Biolabs Group Limited Ordinary Shares | VRAX | Biotechnology | 1.63 | 7.08M | 6.54% | n/a | 4.18% |
Purple Biotech Ltd | PPBT | Biotechnology | 4.49 | 7.07M | 2.75% | n/a | 0.89% |
CDIO | CDIO | Biotechnology | 0.231 | 7.07M | 9.53% | n/a | 28.31% |
Galmed Pharmaceuticals Ltd | GLMD | Biotechnology | 4.68 | 7.05M | 23.16% | n/a | 0.00% |
Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 2.69 | 6.99M | 6.32% | n/a | -4.26% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.56 | 0.53 | Par |
Ent. to Revenue | 0.52 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.69 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 107.95 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 7.32M | 3.66B | Emerging |